The Technical Analyst
SAGE Therapeutics Inc [SAGE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
SAGE Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.47% $12.95
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 778.38 mill |
| EPS: | -9.05 |
| P/E: | -1.430 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 60.11 mill |
| Avg Daily Volume: | 0.998 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.430 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.24x |
| Company: PE -1.430 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 12.04 - 13.86 ( +/- 7.05%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-13 | Greene Barry E | Buy | 168 000 | Stock Option (Right to Buy) |
| 2024-02-13 | Cook Anne Marie | Buy | 11 250 | Common Stock |
| 2024-02-13 | Cook Anne Marie | Buy | 22 500 | Stock Option (Right to Buy) |
| 2024-02-13 | Gault Laura | Buy | 22 500 | Stock Option (Right to Buy) |
| 2024-02-13 | Gault Laura | Buy | 11 250 | Common Stock |
| INSIDER POWER |
|---|
| 92.61 |
| Last 97 transactions |
| Buy: 1 228 960 | Sell: 86 892 |
Forecast:
16:00 - $12.95
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $12.95
Forecast 2: 16:00 - $12.95
Forecast 3: 16:00 - $12.95
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $12.95 (0.47% ) |
| Volume | 0.807 mill |
| Avg. Vol. | 0.998 mill |
| % of Avg. Vol | 80.82 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SAGE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $23.78 | N/A | Active |
|---|
SAGE
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-17 06:30:00 - Press Release
Sage Therapeutics Announces Topline Results From Phase 2 Precedent Study Of Dalzanemdor (sage-718) In The Treatment Of Mild Cognitive Impairment In Parkinson's Disease
Cambridge, mass.--(business wire)--sage therapeutics, inc. (nasdaq: sage) announced today topline results from precedent, a double-blind, placebo-controlled phase 2 study of the investigational oral medicine dalzanemdor (sage-718) in people with mild cognitive impairment (mci) in parkinson's disease (pd). the precedent study did not meet its primary endpoint of demonstrating statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on.
2024-04-11 06:30:00 - Press Release
Sage Therapeutics To Report First Quarter 2024 Financial Results On Thursday, April 25, 2024
Cambridge, mass.--(business wire)--sage therapeutics, inc. (nasdaq: sage), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on thursday, april 25, 2024 at 8:00 a.m. et to review first quarter 2024 financial results and discuss recent business updates. the webcast can be accessed on the investor page of sage's website at investor.sagerx.com. a replay of the webcast will be available following the completion o.
2024-02-28 06:30:00 - Press Release
Sage Therapeutics To Present At Upcoming March Investor Conferences
Cambridge, mass.--(business wire)--sage therapeutics, inc. (nasdaq: sage), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the company will present at the following upcoming investor conferences in march: td cowen 44th annual health care conference (boston, ma): fireside chat on tuesday, march 5, 2024 at 2:50 p.m. et. stifel 2024 virtual cns days (virtual): fireside chat on tuesday, march 19, 2024 at 1:30 p.m. et. a live webcast of ea.
2024-02-14 06:30:00 - Press Release
Sage Therapeutics Announces Fourth Quarter And Full Year 2023 Financial Results And Highlights Pipeline And Business Progress
Cambridge, mass.--(business wire)--sage therapeutics, inc. (nasdaq: sage), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended december 31, 2023. “2023 was a pivotal year for sage, with key accomplishments achieved across our pipeline, culminating with the recent encouraging launch of zurzuvae, the first-and-only once daily oral treatment for adults with postpa.
2024-01-31 06:30:00 - Press Release
Sage Therapeutics To Report Fourth Quarter And Full Year 2023 Financial Results On Wednesday, February 14, 2024
Cambridge, mass.--(business wire)--sage therapeutics, inc. (nasdaq: sage), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on wednesday, february 14, 2024 at 8:00 a.m. et to review fourth quarter and full year 2023 financial results and discuss recent business updates. the webcast can be accessed on the investor page of sage's website at investor.sagerx.com. a replay of the webcast will be available followi.
Latest News
2024-04-18 12:41:16 - Zacks Investment Research
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
2024-04-17 15:11:53 - Schaeffers Research
2 Well-Priced Stocks Staging Big Swings Today
Depending on who you ask, a recession is either right around the corner or the stock market is ready to rattle off a seismic bull run.
2024-04-17 09:42:00 - Market Watch
Sage Therapeutics' stock plunges as Parkinson's drug trial disappoints
Sage Therapeutics Inc. shares dropped 17% early Wednesday after the company said its experimental treatment for mild cognitive impairment in patients with Parkinson's disease fell flat in a clinical trial.
2024-04-17 07:32:11 - Reuters
Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study
Sage Therapeutics said on Wednesday it will stop development of its experimental drug to treat Parkinson's disease after it failed a mid-stage study, sending the company's shares down 4% before the bell.
2024-04-11 06:30:00 - Business Wire
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET to review first quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion o.
2024-03-15 12:35:42 - Zacks Investment Research
Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report?
2024-02-28 06:30:00 - Business Wire
Sage Therapeutics to Present at Upcoming March Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in March: TD Cowen 44th Annual Health Care Conference (Boston, MA): fireside chat on Tuesday, March 5, 2024 at 2:50 p.m. ET. Stifel 2024 Virtual CNS Days (Virtual): fireside chat on Tuesday, March 19, 2024 at 1:30 p.m. ET. A live webcast of ea.
2024-02-15 14:41:06 - Zacks Investment Research
Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates
Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae.
2024-01-31 06:30:00 - Business Wire
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, February 14, 2024 at 8:00 a.m. ET to review fourth quarter and full year 2023 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available followi.
2024-01-02 06:30:00 - Business Wire
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco, CA. A live webcast of the presentation can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the co.